| Name | Title | Contact Details |
|---|
As Floridas best bank according to Forbes and our customers, BayFirst National Bank proudly serves Tampa Bay area families, individuals and businesses through a growing network of local banking centers while also helping businesses move forward through its nationwide small business lending division. We provide tailored banking products, personalized service, innovative financial solutions, and the latest in technology to help our customers reach their goals. At BayFirst, our employees are our strongest asset, and we are committed to providing them with everything they need to succeed, including personal development opportunities, highly competitive compensation, and one of the most robust benefits packages around. Focusing on culture and our professional atmosphere, we also continuously work to build an institution where people are proud to work, and we do so by encouraging open communication in an environment of mutual respect. Member FDIC l Equal Housing Lender l NMLS# 806183
Mymcpl is a Missouri-based nonprofit organization that provides notary, remote printing, and passport services for individuals.
Based in North Carolina, the partnership of UNX and Christeyns brings together more than 100 years of experience in the textile care industry. Specializing in commercial quality cleaning chemicals for the laundry, housekeeping, warewashing, and dry and wet cleaning markets, these products are supported with custom designed dispensing equipment to produce high efficiency results for customers. Learn more by calling 800-869-6171 for more information or by visiting our website.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.